Scarica l'app Stockscreener
3.01
2.73%
0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.93
Aprire:
$2.93
Volume 24 ore:
465.41K
Relative Volume:
0.47
Capitalizzazione di mercato:
$500.64M
Reddito:
-
Utile/perdita netta:
$-54.70M
Rapporto P/E:
-9.1212
EPS:
-0.33
Flusso di cassa netto:
$-51.36M
1 W Prestazione:
+14.02%
1M Prestazione:
+7.12%
6M Prestazione:
-17.53%
1 anno Prestazione:
-39.31%
Intervallo 1D:
$2.89
$3.02
Intervallo di 1 settimana:
$2.60
$3.047
Portata 52W:
$2.31
$5.31
Savara Inc Stock (SVRA) Company Profile
Nome
Savara Inc
Settore
Industria
Telefono
51285113796
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Confronta SVRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
3.01 | 500.64M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-11-13 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-11-07 | Iniziato | Guggenheim | Buy |
| 2023-05-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2021-03-16 | Iniziato | Piper Sandler | Overweight |
| 2021-03-15 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-13 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Ripresa | ROTH Capital | Neutral |
| 2018-01-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-09-27 | Ripresa | ROTH Capital | Buy |
| 2017-09-22 | Iniziato | Jefferies | Buy |
| 2017-09-11 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Savara Inc Borsa (SVRA) Ultime notizie
Savara Inc. Announces Equity Awards for New Employees - MSN
Savara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Sells 4,330 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA) - Defense World
Savara Announces New Employment Inducement Grant | SVRA Stock Ne - GuruFocus
Savara Announces New Employment Inducement Grant - Bluefield Daily Telegraph
Savara Inc (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara to present aPAP treatment study at medical congresses By Investing.com - Investing.com Canada
Savara to present aPAP treatment study at medical congresses - Investing.com
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - MarketScreener
Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management - Stock Titan
259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc. - Defense World
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN
Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - marketscreener.com
Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia
Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - MarketScreener
Savara director David Ramsay acquires $416,250 in common stock - Investing.com India
Q1 Earnings Forecast for Savara Issued By HC Wainwright - The AM Reporter
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com South Africa
SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Savara Inc ends sales agreement with Evercore By Investing.com - Investing.com South Africa
Savara Inc ends sales agreement with Evercore - Investing.com
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com India
Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
What is HC Wainwright’s Estimate for Savara Q1 Earnings? - Defense World
HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA) - Defense World
Savara enters loan and security agreement with Hercules Capital - MSN
Savara stock holds Buy rating, $6 target from H.C. Wainwright By Investing.com - Investing.com Australia
Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India
Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
Savara Inc. (SVRA) reports earnings - Quartz
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe
Breakthrough: Savara Advances First-Ever aPAP Treatment with FDA Filing, Reports $196M Cash Position - Stock Titan
JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa
JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India
Savara secures $200M loan to support respiratory drug launch By Investing.com - Investing.com South Africa
Savara Inc Azioni (SVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Savara Inc Azioni (SVRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):